Riskpilot← Back to searchSign inGet full accessMannaCell Biotech AB
ABActiveOrg 5593178246Wholesale of other household goods · NACE 4649Est. 20210 employees
Revenue 2025
SEK 0
EBITDA margin
—
+21% vs 2024
Equity ratio
100.0%
Financial strength
Net profit 2025
SEK -8K
+21% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -8K | +21% |
| Net profit | SEK -8K | +21% |
| Total assets | SEK 28K | -23% |
| Equity | SEK 28K | -23% |
| Employees | 0 | — |
Legal name
MannaCell Biotech AB
Org number
5593178246
Legal form
Aktiebolag
NACE code
4649 · Wholesale of other household goods
Founded
18 maj 2021
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Vårt företag bedriver forskning och utveckling, försäljning samt relaterade verksamheter inom drycker och kosttillskott. Vi organiserar även regelbundet studiebesök med olika teman, såsom workshops om hållbar utveckling, företags- och skolbesök.
Address
Email
pictonailer@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 51 | 0 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | −2 | 27 | −11 | −8 |
| Depreciation & amort. | — | — | — | — |
| EBIT | −2 | 27 | −11 | −8 |
| Net financials | — | — | — | — |
| Profit before tax | −2 | 27 | −11 | −8 |
| Tax | — | −6 | — | — |
| Net profit | −2 | 21 | −11 | −8 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 23 | 52 | 36 | 28 |
| Equity | 23 | 46 | 36 | 28 |
| Long-term debt | — | — | — | — |
| Short-term debt | 0 | 6 | 0 | — |
| Total debt | — | 6 | — | — |
EBITDA margin
-833100.0%
This company
15.8%
Market median
-5272885% vs market
20222025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20222025
Return on equity
-30.2%
This company
18.4%
Market median
-264% vs market
20222025
Net profit margin
-833100.0%
This company
8.1%
Market median
-10285285% vs market
20222025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-18 – 2022-04-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MannaCell Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tianyou Li | Board of Directors | 0 companies |
| Boning Li | Deputy Board Member | 0 companies |